Data sourcesSEC Form 44h ago
House PTR4h ago
SEC 13F4h ago
Robinhood Chain4h ago
Public companyEditas Medicine, Inc.
EDITCIK 0001650664
Price$2.57
1 year-7.6%
Disclosed transactions10
Buys / sells0 / 6
Max Insider Score15
Connections with evidence6
EDIT · disclosed activity on price
| Score | Actor | Security | Side | Value | Executed | Disclosed | Lag | Source | Evidence |
|---|
| 9 | ONO'Neill Gilmore NeilDirector, CEO | EDITEditas Medicine, Inc. Grant or award | A | — 43.6K sh | Nov 5, 2026 | Nov 6, 2026 |
| 13 | BLBurkly LindaEVP, CHIEF SCIENTIFIC OFFICER | EDITEditas Medicine, Inc. Grant or award | A | — 16.5K sh | Nov 5, 2026 | Nov 6, 2026 traded Nov 5, 2026 | +1d | SEC Form 4 | |
| 9 | OSOry Daniel ScottEVP, Chief Medical Officer | EDITEditas Medicine, Inc. Grant or award | A | — 950.0K sh | Sep 8, 2026 | Sep 9, 2026 traded Sep 8, 2026 | +1d | SEC Form 4 | |
| 11 | BLBurkly LindaEVP, CHIEF SCIENTIFIC OFFICER | EDITEditas Medicine, Inc. Open-market sale · 10b5-1 plan | SELL | $2,153 709 sh | Sep 3, 2026 | Sep 4, 2026 traded Sep 3, 2026 | +1d | SEC Form 4 | |
| 11 | PAParison AmySVP, Chief Financial Officer | EDITEditas Medicine, Inc. Open-market sale · 10b5-1 plan | SELL | $1,376 453 sh | Sep 3, 2026 | Sep 4, 2026 traded Sep 3, 2026 | +1d | SEC Form 4 | |
| 11 | ONO'Neill Gilmore NeilDirector, CEO | EDITEditas Medicine, Inc. Open-market sale · 10b5-1 plan | SELL | $16K 5,124 sh | Sep 3, 2026 | Sep 4, 2026 traded Sep 3, 2026 | +1d | SEC Form 4 | |
| 9 | ETEllinor Patrick Thomas IIDirector | EDITEditas Medicine, Inc. Grant or award | A | — 103.4K sh | Aug 6, 2026 | Aug 7, 2026 traded Aug 6, 2026 | +1d | SEC Form 4 | |
| 15 | ONO'Neill Gilmore NeilDirector, CEO | EDITEditas Medicine, Inc. Open-market sale · 10b5-1 plan | SELL | $12K 5,603 sh | Dec 3, 2025 | Dec 4, 2025 traded Dec 3, 2025 | +1d | SEC Form 4 | |
| 15 | PAParison AmySVP, Chief Financial Officer | EDITEditas Medicine, Inc. Open-market sale · 10b5-1 plan | SELL | $993 461 sh | Dec 3, 2025 | Dec 4, 2025 traded Dec 3, 2025 | +1d | SEC Form 4 | |
| 15 | BLBurkly LindaEVP, CHIEF SCIENTIFIC OFFICER | EDITEditas Medicine, Inc. Open-market sale · 10b5-1 plan | SELL | $1,535 713 sh | Dec 3, 2025 | Dec 4, 2025 traded Dec 3, 2025 | +1d | SEC Form 4 | |
SVP, Chief Financial Officer · Dec 4, 2025